BTIG lowered the firm’s price target on NeoGenomics (NEO) to $12 from $17 and keeps a Buy rating on the shares. The firm cites the company’s Q1 revenue miss and a lower revenue guide for its acquired Pathline business, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics: Hold Rating Amid Mixed Financial Performance and Market Conditions
- NeoGenomics Reports Strong Q1 2025 Performance
- NeoGenomics Reports Strong Q1 2025 Earnings Growth
- Optimistic Buy Rating for NeoGenomics Amid CEO Transition and Growth Potential
- Challenging Growth Outlook and Competitive Pressures Lead to Hold Rating for NeoGenomics